A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases - Top-Institutions - MDSpire

A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases

  • By

  • Sebastian Jeising

  • Ann-Christin Nickel

  • Johanna Trübel

  • Jörg Felsberg

  • Daniel Picard

  • Gabriel Leprivier

  • Marietta Wolter

  • My Ky Huynh

  • Marlene B. Olivera

  • Kerstin Kaulich

  • Lena Häberle

  • Irene Esposito

  • Gunnar W. Klau

  • Julia Steinmann

  • Thomas Beez

  • Marion Rapp

  • Michael Sabel

  • Sascha Dietrich

  • Marc Remke

  • Jan F. Cornelius

  • Guido Reifenberger

  • Nan Qin

  • July 10, 2024

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Cancer Biology
    • Precision Medicine

  • #2

    Dana-Farber Cancer Institute / Brigham and Women's Hospital
    Dana-Farber Cancer Institute / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Translational Cancer Research
    • Molecular Pathology

  • #3

    Heinrich Heine University Düsseldorf
    Heinrich Heine University Düsseldorf

    Düsseldorf, North Rhine-Westphalia

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Cancer Pharmacology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neuro-oncology
    • Cancer Genomics
    • Precision Oncology

  • #5

    Massachusetts General Hospital Cancer Center
    Massachusetts General Hospital Cancer Center

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Cancer Pharmacology
    • Translational Medicine

Original Source(s)

A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases

  • by Sebastian Jeising, Ann-Christin Nickel, Johanna Trübel, Jörg Felsberg, Daniel Picard, Gabriel Leprivier, Marietta Wolter, My Ky Huynh, Marlene B. Olivera, Kerstin Kaulich, Lena Häberle, Irene Esposito, Gunnar W. Klau, Julia Steinmann, Thomas Beez, Marion Rapp, Michael Sabel, Sascha Dietrich, Marc Remke, Jan F. Cornelius, Guido Reifenberger, Nan Qin

  • July 10, 2024

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report